A001 Comparative assessment of response and acute toxicities in inoperable carcinoma esophagus undergoing concurrent chemoradiation with two different chemo regimens: An interim analysis of phase III clinical trial. Divyesh Kumar, Post Graduate Institute of Medical Education and Research, Chandigarh, India.

A002 Clinical outcome of belotecan as second-line treatment for recurrent small cell lung cancer: A phase Ib randomized multicenter study. Hye Ryun Kim, Yonsei Cancer Center, Yonsei University College of Medicine, Seoul, South Korea.

A003 An umbrella study of biomarker-driven targeted therapy in patients with platinum-resistant recurrent ovarian cancer: AMBITION. Jung-Yun Lee, Yonsei University, Seoul, Korea.

A004 Expression of PDGFRα, ligands, and related genes versus clinical outcomes in a phase 1B/2 study of olaratumab plus doxorubicin in soft tissue sarcoma. Sae Young Lee, Eli Lilly and Company, Seoul, Korea.

A005 Olaratumab after treatment with olaratumab + doxorubicin: Monotherapy outcomes from the JGDG phase 2 clinical trial. Sae Young Lee, Eli Lilly and Company, Seoul, Korea.

A006 T cell ratio of tumor infiltrating lymphocytes in HER2+ and triple negative breast cancer patient. Sung-hee Park, Pusan National University Hospital, Pusan National University College of Medicine, Busan, South Korea.

A007 CCND1 splice variant as a novel diagnostic and prognostic biomarker for thyroid cancer. Chan Kwon Jung, The Catholic University of Korea, Seoul St. Mary's Hospital, Seoul, Republic of Korea.

A008 GenesWell™ ddEGFR Mutation Test is a valuable diagnostics to identify NSCLC patients for EGFR-TKI treatment. Dayeon Ryu, R&D Center, Gencurix Inc., Seoul, Republic of Korea.


A010 The development of a new detection method of colorectal cancers from patients’ blood using rpS3 antibody and dot blot. Joon Kim, Div of Life Sciences, Korea University, Seoul, Korea.
Poster Session A
Thursday, November 15, 2018
17:15–19:30

A011 Discordance between the BCT score and Oncotype DX recurrence score for risk classification in Asian women 50 years of age or younger with clinical low-risk, hormone receptor-positive, HER2-negative lymph node-negative breast cancer. Mi Jeong Kwon, Kyungpook National University, Daegu, Republic of Korea.

A012 The complementary role of microsatellite instability and single patient classifier for stage II/III gastric cancer: Results from the CLASSIC trial. Yoon Young Choi, Yonsei University Health System, Seoul, Republic of Korea.


A014 Interim- and posttreatment response to neoadjuvant chemotherapy assessed by 18F-FDG PET/CT for the prediction of outcome in osteosarcoma of the extremities. Byung hyun Byun, Korea Cancer Center Hospital, Korea Institute of Radiological and Medical Sciences (KIRAMS), Seoul, Republic of Korea.


A016 Predicting pathological noninvasiveness in T1 non-small cell lung cancer on chest CT scan using deep learning algorithm. Kyongmin Beck, Seoul St. Mary’s Hospital, College of Medicine, The Catholic University of Korea, Seoul, Republic of Korea.

A017 In vivo single cell tracking with PET using radiolabeled mesoporous silica nanoparticles. Kyung Oh Jung, Stanford University School of Medicine, Palo Alto, CA, USA.

A018 [18F]FDG PET/MRI in gastric cancer patient-derived xenografts. Seong-Woo Bae, Cancer Research Institute, Seoul National University College of Medicine, Seoul, Republic of Korea.

A019 Utility of 18F FDG-PET/CT for predicting pathologic complete response of luminal HER2-negative breast cancer patients receiving neoadjuvant chemotherapy. Yee Soo Chae, Kyungpook National University Chilgok Hospital, Daegu, Republic of Korea.

A020 Expression of Stathmin1 in gastric adenocarcinoma. Bat-Erdene Batsaikhan, Mongolian National University of Medical Sciences, Ulaanbaatar, Mongolia.

A021 Comprehensive molecular classification of bladder cancer reveals distinct prognostic subgroups with different sensitivities to immunotherapy. Bic-Na Song, Korea Research Institute of Bioscience and Biotechnology, Daejeon, Korea.
A022 Is NF2 a key player of the differentially expressed gene between spinal cord ependymoma and intracranial ependymoma? Chun Kee Chung, Seoul National University, Seoul, Korea.

A023 Dysregulation of microRNA machinery components in clear cell renal cell carcinoma. Dongeon Kim, Department of Immunology, School of Medicine, Keimyung University, Daegu, South Korea.

A024 PHLI-seq identifies genetic variances in single cell-isolated CD133 positive human colon cancer cells. Dong-Wook Min, Seoul National University, Seoul, South Korea.

A025 Mutational analysis of radiotherapy-naive versus -recurrrent tumors in uterine cervical cancer. Endang Nuryadi, Gunma University Graduate School of Medicine, Maebashi, Gunma, Japan.

A026 Targeting of QKI by miR-200 promotes epithelial-to-mesenchymal transition and tumor growth. Eun Ju Kim, College of Medicine, Ewha Womans University, Seoul, Korea.

A027, PP1 Targeted sequencing analysis of pulmonary adenocarcinoma with multiple synchronous ground-glass/lepidic nodules. Eunhyang Park, Seoul National University Bundang Hospital, Seoul National University College Of Medicine, Seongnam, Republic of Korea.


A029 Novel recurrent or clinically-actionable in-frame gene fusions in diffuse gastric cancer. Hanna Yang, National Cancer Center, Goyang, Gyeonggi, Republic of Korea.

A030 Establishment of a large-scale drug sensitivity screening platform on gastric cancer organoid cultures with potential to guide treatment. Helen HN Yan, Department of Pathology, The University of Hong Kong, Hong Kong.


A032 The interaction of HOX transcript antisense intergenic RNA (HOTAIR) single nucleotide polymorphism and risk of colorectal cancer in Koreans. Jeong yong Lee, College of Life Science, CHA University, Seongnam, gyeonggi-do, Republic of Korea.
A033 Gene and environment interaction relevant to estrogen and risk of breast cancer: Should gene and environment interaction be detected only among significant SNPs from GWAS? JooYong Park, Seoul National University Graduate School, Seoul, Republic of Korea.

A034 Comparison of a next-generation sequencing panel from the K-MASTER project with orthogonal methods for the detection of KRAS/NRAS/BRAF mutations in colorectal cancer and HER2 amplifications in breast cancer. Jung Yoon Choi, Korea University Anam Hospital, Seoul, Republic of Korea.

A035 Comparison of genomic profiles of primary and matched metastatic tissues in patients with colorectal cancer by using the Ion AmpliSeq Cancer Hotspot Panel. Jung Yoon Choi, Korea University Anam Hospital, Seoul, Republic of Korea.


A037 Regorafenib can reverse SPHK1 associated oxaliplatin resistance in colon cancer cell line. Se Jun Park, Seoul St. Mary's Hospital, The Catholic University, Seoul, Republic of Korea.

A038 miniABS: An absolute, single-sample subtype classifier of breast cancer with 11 functional genes. Mi-kyoung Seo, Yonsei University College of Medicine, Seoul, Republic of Korea.

A039 Prevalence of abnormal microsatellite instability among ovary and endometrial cancer patients. Min Kyu Kim, Sungkyunkwan University of Medicine, Samsung Changwon Hospital, Changwon-si, Republic of Korea.


A041 Functional annotation of non-coding variants to infer effects on melanoma initiation. Paula Godoy, Washington University in St. Louis, St. Louis, MO, USA.

A042 Ursolic acid plus paclitaxel inhibit metastasis of esophageal cancer cells by suppression of FOXM1. RUOYU MENG, Institute for Medical Sciences, Chonbuk National University Medical School, Jeonju, Jeollabuk-do, Republic of Korea.

A043 Gaps in willingness to undergo BRCA 1/2 testing, communicate its results, and undergo risk reduction surgery among general public, cancer patients, and health-care professionals. Seung Yeon Cho, National Cancer Center, Goyang, Republic of Korea.
A044 Precise therapy rescues one advanced breast cancer patient with VUS BRCA2 mutant. Song Peng Li, Department of Thyroid Breast & Vascular Surgery, Xijing Hospital, Fourth Military Medical University, Xi’an, Shaanxi, China.

A045 Association between 21-gene recurrence-score and PIK3CA mutation in ER-positive/HER2-negative breast cancer. Sung Gwe Ahn, Gangnam Severance Hospital, Yonsei University College of Medicine, Seoul, Republic of Korea.

A046 A robust genomic signature to predict distant metastasis among stage I lung adenocarcinoma patients. Sungjune Kim, Moffitt Cancer Center, Tampa, FL, USA.

A047 High tumor purity of patient-derived organoids allow accurate depiction of pancreatic adenocarcinoma subtypes. Sungsoo Kim, Seoul National University, Seoul, Republic of Korea.

A048 Transcription factor E2F1 is associated with the homologous recombination activity by RAD54L in bladder cancer cells. Sun-Hee Leem, Dong-A University, Busan, Republic of Korea.

A049 Next-generation sequencing-based molecular characterization of urothelial carcinoma in Korean patients from the K-MASTER project. Yoon Ji Choi, Korea University Anam Hospital, Seoul, Republic of Korea.

A050 Genomic analysis of brain metastasis from ovarian/ peritoneal cancer. Youn Jin Choi, Seoul St.Mary’s Hospital, Seoul, Republic of Korea.


A052 The selective inhibitor of HDAC6 induces apoptosis and synergizes with BTK inhibitor Ibrutinib in follicular lymphoma. Dong Hoon Lee, Yonsei University, Incheon, Republic of Korea.

A053 HDAC6-selective inhibitor has effective and potent anticancer activity in AIRD1A-mutated ovarian cancers. Go Woon Kim, College of Pharmacy, Yonsei Institute of Pharmaceutical Sciences, Yonsei University, Incheon, Republic of Korea.

A054, PP3 TET1-mediated 5-hydroxymethylcytosine alteration in the pathogenesis of medulloblastoma. Hyerim Kim, Emory University, Atlanta, GA, USA.

A055 Temozolomide-resistant glioblastoma depends on HDAC6 activity through regulating MMR. Soo-Keun Yeon, College of Pharmacy, Yonsei Institute of Pharmaceutical Sciences, Yonsei University, Incheon, Republic of Korea.
A056 Altered expression of the T-cell regulators on the glioblastoma cells can be epigenetically modulated by the histone methylase or demethylase and influence on the prognosis of the glioblastoma patients. Young Zoon Kim, Sungkyunkwan University, Changwon, Republic of Korea.

A057 Alternative splicing associated with epigenetic interactions between miRNA and DNA methylation in bladder cancer. Younghee Lee, University of Utah School of Medicine, Salt Lake City, UT, USA.

A058 Transcription factor Sp1 prevents TRF2ΔBΔM-induced premature senescence in human diploid fibroblasts. Hyeon Ju Lee, Kangwon National University School of Medicine, Chuncheon, Republic of Korea.


A060 Novel combination of quercetin and benzyl isothiocyanate synergistically boosted the death of breast adenocarcinoma cells. Muhamad Hatib A Rahaman, School of Fundamental Science, Universiti Malaysia Terengganu, Kuala Terengganu, Terengganu, Malaysia.

A061 Cytotoxicity, apoptosis induction, and cell cycle modulation of curcumin and pentagamavunon-1 on 4T1 breast cancer cell. Retno Murwanti, Faculty of Pharmacy, Yogyakarta, DIY, Indonesia.

A062 Curcumin suppresses oncogenicity of human colon cancer cells by covalently modifying the cysteine 67 residue of SIRT1. Yeon-Hwa Lee, Tumor Microenvironmnet Global Core Research Center, College of Pharmacy, Seoul National University, Seoul, Republic of Korea.


A064 Tumor heterogeneity regarding radiosensitivity, recurrence risk, and PD-L1 in breast cancer: Transcriptome analysis of single-cell RNA sequencing data. Bum-Sup Jang, Seoul National University Hospital, Seoul, Republic of Korea.

A066 The expansion by the IL-33 contribute to accumulation of regulatory T cells in the tumor microenvironment. Jimin Son, Yonsei University, Seoul, Republic of Korea.


A068 Adipocytes up-regulates CD36 expression, fatty acid uptake, and oxidation: Enhancing breast cancer cell progression. Jones Gyalmi, Yonsei University, Incheon, Yeonsu-gu, Republic of Korea.

A069 The metabolic comparison between normal and lung cancer cell lines in the anoikis condition. MUNKI CHOO, College of Pharmacy, Seoul National University, Seoul, Republic of Korea.


A073 COL1A1 as predictive marker of chemoresistance in gastric cancer. Seon Jin Lee, Pusan National Univeristy Hospital, Busan, Republic of Korea.

A074 Effects of CAF-specific microRNAs on lung cancer progression and metastasis. Sieun Lee, College of Medicine, Ewha Womans University, Seoul, Korea.

A075 Histon deacetylase Sirt6 inhibits hepatocellular carcinoma cell growth through down-regulating β-catenin. Cong Shan Li, Hepatocellular Carcinoma Cells, Jeonju, Jeonlabuk-do, Republic of Korea.

A076 Discovery of recurrence-specific mutations using machine learning in breast cancer. Han-Jun Cho, CHA University School of Medicine, Seongnam, Gyeonggi, Republic of Korea.

A077 Clinical characteristics and treatment pattern of bladder cancer with non-urothelial histology in Korea. Hee Yeon Lee, Incheon St. Mary’s Hospital, Incheon, Republic of Korea.

A078 Observation of acetyl phosphate formation in mammalian mitochondria using real-time in-organelle NMR metabolomics. Hoonsik Nam, College of Pharmacy, Seoul National University, Gwanak-gu, Seoul, Republic of Korea.

A079 Inactivation of SREBP1 and SREBP2 with HN1 suppresses hepatocellular carcinoma. Hua Jin, Institute for Medical Science, Chonbuk National University Medical School, Jeonju, Jeonlabuk-do, Republic of Korea.

A081 Comprehensive molecular characterization and clinical utility of gastric cancer patient-derived xenograft (PDX). Jae Eun Lee, Yonsei Biomedical Research Institute, Yonsei University College of Medicine, Seoul, Republic of Korea.

A082 GNAQ alteration is associated with metastasis through regulation of RANKL. Ji-Yoon Choi, Samsung Medical Center, Seoul, Republic of Korea.

A083 Synergistic anti-cancer effects of AKT and SRC inhibition in human pancreatic cancer cells. Jongbeom Oh, CHA Bundang Medical Center, CHA University School of Medicine, Seongnam, Gyeonggi-do, Republic of Korea.

A084 De novo transcriptome analysis to search for the function of lichen on gastric and colon cancer cells. Woo Kyun Bae, Chonnam National University Hwasun Hospital, Hwasun, Republic of Korea.


A086 Measurement of anxiety and depression among cancer patients seen in an outpatient clinic of a tertiary hospital using the validated Hospital Anxiety and Depression Scale – Pilipino Version (HADS-P). Kenneth Samala, UP-Philippine General Hospital, Manila, Philippines.

A087 Metastatic melanoma to the heart presenting as third degree atrioventricular block: A case report. Kenneth Samala, UP-Philippine General Hospital, Manila, Philippines.

A088 Prolonged MEK inhibition leads to acquired resistance and increased invasiveness in KRAS mutant gastric cancer. Kyoung-Min Choi, Graduate School of Analytical Science and Technology (GRAST), Chungnam National University, Daejeon, Republic of Korea.

A089 The anticoagulation treatments with 6-month clinical outcomes in cancer patients having venous thromboembolism (VTE). Min Hee Hong, Yonsei Cancer Center, Severance Hospital, Yonsei University College of Medicine, Seoul, Republic of Korea.

A090 Artemisia capillaris extract induces apoptosis and anti-angiogenesis via blocking PI3K/AKT signaling in HCC. Min Ji Cheon, Inha University, Incheon, Republic of Korea.

A091 Successful desensitization of patients with oxaliplatin and cetuximab hypersensitivity: A single-center experience with 5 patients. Myoung Joo Kang, Inje University Haeundae Paik hospital, Busan, Republic of Korea.